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Graphical Abstract 
 
Forming propylene glycol (PG) rich solvent supramolecular structures in human skin enhances the 
epidermal localisation of diclofenac (D) upon topical administration.
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Abstract 
 
The preferential localisation of drug molecules in the epidermis of human skin is considered 
advantageous for a number of agents, but achieving such a delivery profile can be 
problematic. The aim of the present study was to assess if the manipulation of solvent 
supramolecular structuring in the skin could be used to promote drug residence in the 
epidermal tissue. Skin deposition studies showed that a 175-fold increase in the epidermal 
loading of a model drug diclofenac (138.65 ± 11.67 µg.cm-2), compared a control (0.81 ± 
0.13 µg.cm-2), could be achieved by co-localising the drug with a high concentration of 
propylene glycol (PG) in the tissue. For such a system at 1 h post-dose application the PG 
flux was into the skin was 9.3 mg.cm
2
.h
-1
 and the PG:water ratio in the epidermis was 76:24 
(v/v). At this solvent ratio infrared spectroscopy indicated that PG rich supramolecular 
structures, which displayed a relatively strong physical affinity for the drug, were formed. 
Encouraging the production of the PG-rich supermolecular structures in the epidermis by 
applying diclofenac to the skin using a high PG loading dose (a 240 µg.cm-2) produced an 
epidermal:transdermal drug distribution of 6.8:1. However, generating water-rich solvent 
supermolecular structures in the epidermis by applying diclofenac using a low PG loading 
dose (2.2 µg.cm-2), led to a loss of preferential epidermal localisation of diclofenac in the 
tissue (0.7:1 epidermal:transdermal drug distribution). This change in diclofenac skin 
deposition profile in response to PG variations and the accompanying FTIR data supported 
the notion that supramolecular solvent structures could control drug accumulation in the 
human epidermis. 
 
Keywords: Human skin; topical delivery; supramolecular structuring; propylene glycol; 
diclofenac. 
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Introduction 
 
The human skin is a highly stratified organ. Its different layers show diversity in their 
composition. For example, the water content in the outermost layer, the stratum corneum, is 
ca. 20% w/w, in the underlying viable epidermis it is 60% w/w whilst in the dermis, which is 
innovated by blood, it is > 70% w/w 
1, 2
. When drugs are applied topically to the skin the 
different characteristics of the layers dictate the regions in which the administered agents will 
preferentially reside. The distribution of a drug in the skin can be modified by altering the 
contents of important components already in the skin, e.g., Solaraze®, which is thought to 
modify skin hydration, or by delivering molecules into the tissue which modify its properties 
3-5
. Research has shown that the co-localisation of drugs with excipients in the skin is one of 
the most effective means to alter the distribution of the agents in the different skin strata but, 
the drug-excipient interactions that occur in the skin are not yet so well understood that 
topical formulations can be engineered to concentrate a drug in specific strata of the skin and 
this suggests that more work is needed in this field 
6-10
. 
 
It is notable that some of formulation excipients that have been reported to readily pass into 
the skin are also known to also display non-ideal mixing characteristics when combined with 
water (e.g. ethanol 
11
, propylene glycol (PG) 
12-13
 and polyethylene glycol 
14
). This behaviour 
is a consequence of supramolecular structure formation by the molecules in an aqueous fluid. 
However, there have been no previous reports that document how solvent structuring 
influences the manner in which a co-administered drug distributes in skin tissue. It is possible 
that manipulating the formation of solvent supramolecular structures could act as a novel 
means to achieve epidermal localisation of an active therapeutic agent. However, this would 
require the level of the excipient to be controlled such that physical interactions that occur 
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between the supramolecular structures and the drug promote its retention within a particular 
layer of the tissue. To evaluate this potential mechanism of skin penetration enhancement 
more research is required to establish the nature of the interactions between topically applied 
drugs and co-localised excipients. 
 
Solvent supramolecular structures do not form covalent bonds with therapeutic agents and 
facilitate their transport as a drug solvent complex, rather they penetrate into barriers and co-
localise with drug molecules. Once in the tissue they are thought to modify the drug-tissue 
association by the competitive formation of drug-solvent bonds that occur through a range of 
temporal physical interactions; which include hydrophobic, electrostatic and hydrogen bond 
formation 
15-17
. Drug-solvent and drug-tissue interactions form an equilibrium that is highly 
dynamic and dependant on the solvent-solvent structuring 
18,19
. For non-ideally mixed 
systems these solvent-solvent structures can be very diverse in nature and can change 
depending upon the exact ration of molecules present in the solvent. For example, Dixt et al., 
has reported that non-ideally mixed clusters of water and methanol could produce water 
structures of between 2-20 molecules in a methanol-rich mixture 
16 
and methanol clusters of 
between 3-8 molecules in a water-rich solvent mixture 
15
. Whilst the exact size of these 
clusters have yet to be measured from their combined molecular mass it is evident that they 
could provide a complex with suitable properties that once generated within the skin strata 
might bind small molecular weight drugs in order to encourage co-localisation.  
 
Recent studies that have shown PG-water solvent structuring can be used to manipulate drug 
transport through confluent barriers 
12
. This work demonstrated that propylene glycol (PG), a 
diol widely used in topical formulations and known to form solvent supramolecular structures 
with water 
12-13
, acted by non-covalent binding to the drug within the barrier after topical 
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administration. The aim of the present study was to investigate whether through the control of 
PG solvent supramolecular structuring in the applied dosage form and in the skin the 
distribution of topically applied drugs within the human skin could be manipulated. A dual 
pump spray, described in a previous study 
20
, which allowed a drug to be delivered at a high 
level of drug saturation in a PG-water cosolvent, was utilised to deliver a model drug to the 
surface of the skin. Diclofenac was selected as the model agent as it was known to pass 
through the skin and its permeation was known to be influenced by PG 
12
. An ex vivo human 
tissue model was used to test the percutaneous penetration of both the PG solvent and drug 
into the skin as it is thought to provide a reliable means to model topical drug delivery in 
man. As previous studies have shown that it is extremely problematic to measure the drug-
solvent interactions once molecules have passed into the skin 
21
, in this work the rate of PG 
transport through the skin was measured and combined with the known rate of water 
transport in order to calculate the co-solvent ratios in the different strata of the tissue. This 
information was used to determine the levels of diclofenac and PG in the each strata of the 
tissue and enabled the final experimental design to be refined. Accordingly the PG loading on 
the surface of the skin was altered, in order to assess whether the solvent supramolecular 
structuring would modify the diclofenac disposition in the human epidermis. 
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Experimental Section 
 
Materials 
 
Diclofenac, as the diethylamine salt (melting point of 154°C, BP grade, 99.9%) was kindly 
donated by Unique Chemicals, India. HPMC (Metolose, grade 65SH, viscosity 50 cP), was a 
gift from Shin-Etsu Chemical Ltd, Japan. Propylene glycol (PG) (ACS reagent grade, 
≥99.5%) was supplied by Sigma Aldrich, UK. Acetonitrile and methanol (high performance 
liquid chromatography (HPLC) grade) were obtained from Fisher Scientific International, 
UK and ethanol (99.7–100% v/v) was provided by BDH Laboratory Supplies, UK. Phosphate 
buffered saline (PBS, pH 7.2, 0.172 M) tablets were supplied by Oxoid Ltd, UK. Sheets of 
silicone membrane (Folioxane®), with a thickness of 120 µm, were purchased from 
Novatech Ltd, France. De-ionised water (electrical conductivity 0.5-1 µS) was used 
throughout this study.   
 
Formulation preparation 
 
The diclofenac-saturated PG solution was produced by adding an excess of the diclofenac 
diethylamine salt (DDEA) to PG, adjusting to pH 3 ± 0.1 with phosphoric acid and 
continually stirring at 25˚C, for 72 h (> 48 h was required to ensure equilibrium solubility 
was attained in PG; the kinetic solubility data to confirm the system had reached equilibrium 
was recorded but is not shown). The DDEA suspension was then centrifuged for 20 min at 
16,060 g (Biofuge pico, Heraeus, Kendro Laboratory Products plc, UK) and the drug-
saturated supernatant removed and used in the work. The final pH of all the drug-saturated 
solutions used in the study was checked and recorded (pH 3 ± 0.1).  
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The drug-supersaturated PG-water vehicle containing diclofenac microparticles (InDicP) was 
generated using a dual-canister pump spray (100 µL metered nozzle), described previously 
20
. 
One canister contained diclofenac-saturated PG and the second contained HPMC (3 % w/v) 
dispersed in an aqueous buffer (PBS, 0.172 M, pH 3). To form the InDicP microparticulate 
formulation in situ, two sprays were simultaneous actuated and allowed to mix spontaneously 
on the surface of the skin to achieve a vehicle composition of 50:50 (v/v) PG:water. A 
comparison of diclofenac permeation across silicone membrane obtained after application 
using the two pump sprays with that recorded after administration of the two solutions using 
a pipette showed no significant difference and this confirmed effective dosing and mixing by 
the pump sprays (data not shown). The applied InDicP formulation contained diclofenac at 
0.42% w/v and HPMC at 1.5% w/v.  
 
Formulation characteristics 
 
Infrared spectroscopy 
 
The molecular interactions that occurred in the pure PG solvent, the pH 3 adjusted water and 
the 50:50 (v/v) PG-water solution were assessed using a demountable universal liquid 
transmission cell system (Omni-Cell, Specac Ltd., UK) fitted with CaF2 windows and a 25 
µm mylar spacer (Specac Ltd., UK) on a spectrum One Fourier transform infrared (FTIR) 
spectrometer (Perkin Elmer Ltd., UK). Deuterated water (D2O) was employed to allow 
visualisation of PG absorption bands in the 1700-1300 cm
-1
 range. All the systems were 
carefully adjusted to a pH of 3.0 ± 0.1 to control the drug’s ionisation. The drug (0.42% w/v) 
and HPMC (1.5% w/v) interactions with the PG, water and the 50:50 (v/v) mixture was 
assessed by solubilising the components in the vehicles and again carefully re-adjusting the 
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pH to 3.0 ± 0.1 prior to analysis. The InDicP was analysed directly upon formation and then 
repeatedly over a 180 min time course. All spectra were produced using 32 scans collected at 
a spectral resolution of 4 cm
-1
 using the Spectrum One software (version 10, Perkin Elmer 
Ltd., UK).  
 
Diclofenac microparticle morphology 
 
The morphology of the in situ assembled diclofenac microparticles (InDiP) was assessed in 
the solution state and compared to a control (equivalent system but in the absence of HPMC) 
using an optical microscope (Olympus BX50F, Japan) at a magnification of ×200.  
 
Diclofenac saturation 
 
The degree of diclofenac saturation in the vehicle of the InDicP formulation was determined 
through the assessment of the drug transmembrane transport and then relating this value to a 
flux-DS calibration curve derived using a 50:50 (v/v) PG:water vehicle (pH 3, containing 
1.5% w/v HPMC), as reported previously 
22
. Diclofenac transmembrane transport was 
assessed in vitro using individually calibrated upright Franz diffusion cells (MedPharm Ltd, 
UK) (diffusional area of ~2.1 cm
2
 and receptor volume of ~10.8 ml) fitted with disks of 
silicone membrane (measured thickness of 124.17 ± 6.01 µm, n = 54) and containing a 
magnetic stirrer in the receiver compartment. The receptor compartment was filled with a 
previously sonicated and filtered receiver phase consisting of 20:80 (v/v) EtOH:PBS (pH 
7.4). The assembled Franz cells were placed into a Variomag
®
 magnetic stirrer plate 
immersed in a water bath (Grant Instruments, UK) and the study was initiated by the 
application of 10 actuations from the dual spray formulation which generated 1 ml of the 
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InDicP system on the apical surface of the silicone membrane. Aliquots of the receiver fluid 
(1 mL) were removed periodically and replaced immediately with the same volume of fresh 
receiver fluid, in order to monitor the diclofenac membrane permeation. The removed 
samples were analysed immediately for diclofenac content by HPLC. All the transport 
experiments were repeated 5 times and all the data were used.  
 
Ex vivo human skin deposition studies 
 
Surgically excised samples of human skin were obtained directly after abdominoplastic 
surgery with informed patient consent and approval from the School of Life Sciences Ethics 
Committee with Delegated Authority, University of Hertfordshire (Reference number: 
07/H0711/72, Protocol LS12/11/06S). Epidermal sheets were prepared using the heat 
separation method 
23
. The prepared epidermal sheets (ES) were blotted dry with tissue paper 
and stored flat, wrapped in aluminium foil at -20°C until use. Diclofenac and propylene 
glycol skin deposition was assessed using individually calibrated Franz-type diffusion cells 
(MedPharm Ltd., Guildford, UK). The 240 µg.cm-2 PG dose studies required the application 
of 1 ml of InDicP. Initially the 240 µg.cm-2 PG dose was compared to a saturated control 
system, Dic, with an equivalent PG loading, equivalent co-solvent composition (50:50 % 
(v/v) PG:water) and HPMC (1.5% w/v) levels, but with DS = 1 using a pre-formed 
homogenous solution of the drug and the excipients. The skin penetration of the diclofenac 
from the two formulations was measured over a time course of 24 h by taking a number of 
samples from the receiver solution of Franz diffusion cells which contained epidermal skin in 
order to establish the permeation profile. Subsequent comparisons were made of diclofenac 
diffusion following the application of a (high) 240 µg.cm-2 PG dose with that attained after 
administration of a (low) 2.2 µg.cm-2 PG loading dose. The latter required the application of 
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2.5 µL (3.3 µg.cm-2) of the InDicP formulation, and only the amount of drug diffused after 24 
h was determined, so as to determine the deposition of drug after that time period (including 
the amount of drug retained in the skin) following a single topical dose. In all the studies the 
Franz diffusion cells were fitted with human ES (two pieces of human abdominal skin were 
used; one for the low PG loading dose and another for the high PG loading dose and saturated 
drug control). Sonicated PBS (0.172 M, pH 7.4) was used as the receiver fluid. The ES was 
maintained at 32°C by immersing the Franz cells in a water bath (Grant Instruments, UK) 
held at 37°C. The donor compartment was covered with parafilm to control water loss during 
the duration of the studies. For the 240 µg.cm-2 PG loading dose and saturated control time-
profile studies, 1 mL aliquots of the receiver fluid were removed at defined time points over a 
24 h time course (this was extended to 26 h due to technical demands of the experiment) and 
replaced immediately with the same volume of fresh receiver fluid, in order to monitor the 
diclofenac and PG penetration. The removed samples were divided to analyse diclofenac (0.5 
ml) and PG (0.5 ml) content as described below. At the end of the skin permeation studies, 
the amount of diclofenac localised in the ES was determined. Each Franz cell was dissembled 
and the donor compartment was swabbed with wet then dry cotton buds (4 in total) and two 
tape strips were used (Henkel consumer adhesives, UK), if required, to ensure the surface of 
the skin was free from the applied formulation (pilot studies showed significant drug 
remained on the surface of the skin for low PG dose studies and hence the 2 tape strips were 
only used in this arm of the study). The cotton tip of the cotton buds and the two tape strips 
from each cell (if used) were then immersed, separately, into 4 mL of 20% v/v ethanol in 
PBS (pH 7.2). The epidermal sheet was then placed into 5 ml acetonitrile. All the samples 
were incubated overnight at 32˚C (shaking water bath at 120 strokes.min
-1
), after which the 
solvent was filtered using 0.2 µm poly(vinylidene fluoride) syringe filters (Whatman®, New 
Jersey) and analysed for diclofenac content using HPLC. All the extraction methods were 
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proven ‘fit for purpose’ as per OECD Guideline for the Testing of Chemicals (2004) 
24
. The 
total % recovery for the mass balance process was 95.35 ± 5.52% (Dic, n =4) and 93.75 ± 
2.21% (InDicP, n =4) for the high PG loading dose and was 89.9 ± 4.7 % (InDicP, n = 5) for 
the low PG loading dose. All the skin permeation experiments were repeated 4-7 times. The 
chemical stability of diclofenac in spent receiver fluid (PBS, 0.172 M, pH 7.4) was assessed 
at three diclofenac concentrations (8.5, 45 and 85 µg.mL-1) over 24 h. The average % 
recovery from the procedure was 101.7 ± 1.77 % (n = 15), which indicated the chemical 
stability of the drug was not influence by the skin tissue matrix. 
 
Diclofenac and propylene glycol quantification  
 
Quantitative determination of diclofenac in the transport studies was performed using a 
reverse phase HPLC system consisting of a Jasco UV detector and pump (Jasco Corporation 
Ltd, UK). The mobile phase comprised acetonitrile:methanol:formate buffer (25 mM) 
(50:20:30 (v/v), pH 3.5) set at a flow rate of 1.2 mL.min
-1
. Diclofenac was eluted from a 
Gemini® C18 (250 × 4.6 mm) stationary phase (Phenomenex, UK) at room temperature 
using a 20 µL injection volume and UV detection at 275 nm. The retention time for 
diclofenac was 7.5 min and the assay was previously shown to be ‘fit for purpose’ 
12
. The 
calibration curves were constructed on the basis of the peak area measurements using 
standard solutions of known diclofenac concentrations dissolved in an identical fluid as the 
receiver phase for the permeation studies and an identical fluid as extraction fluid for the 
recovery studies. 
 
Quantitative determination of PG in the receiver aliquots sampled over the 26-h time period 
of the skin distribution studies was determined indirectly by assessing the increase in 
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diclofenac saturated solubility due to the amount of PG permeating to the receiver fluid, 
using a PG-solubility calibration curve (method modified from Bendas et al., 
8
). Calibration 
solutions containing PG in the range of 0 to 41 mg.mL
-1 
(i.e. 0 to 4% v/v PG) in spent 
receiver fluid were saturated with diclofenac (as described previously for the formulation 
preparation) and the saturated solubility of diclofenac at each PG concentration was 
determined using HPLC. The PG-solubility calibration curved showed a good linearity (R
2
 = 
0.96). The assay LOD was 8.1 mg.mL
-1
, LOQ was 24.6 mg.mL
-1
 and the accuracy was 
determined to be 99.6 ± 10.5 %  (n = 8).  
 
Data analysis 
 
Cumulative amounts of drug (µg) penetrating per unit surface area of the ES (cm
2
) were 
corrected for recovery sample removal and plotted against time (h). The steady-state 
transmembrane transport rate, flux, was taken from the line of best fit over at least 4 time 
points with values above the limit of detection (LOD) of the HPLC assay, and with a linearity 
of R
2
  0.98. The lag time (TL) was obtained by extrapolation of the steady-state gradient 
from each individual Franz cell experiment. The enhancement ratio (ER) was defined as the 
ratio of steady-state flux when applied from InDicP formulation to that produced when 
applied as the saturated control Dic. As two pieces of skin were used for different PG loading 
(necessitated by the time frame of the studies and the size of the donated skin samples) when 
the data were compared from the two different skin donors a ratio of epidermal to dermal skin 
deposition was employed to minimised the influence of donor to donor variability. 
 
Cumulative amounts of PG (mg) penetrating per unit surface area of the ES (cm
2
) were 
corrected for previous sample removal and plotted against time (h). Steady-state flux was 
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taken from the line of best fit over at least 4 time points with values above the limit of 
detection (LOD) of the PG-solubility assay, and with a linearity of R
2
  0.96. All values 
were expressed as their mean ± standard deviation (SD), and statistical analysis of data was 
performed using the statistical package for social sciences SPSS version 16.0 (SPSS Inc., 
Chicago, IL. USA). Normality (Sapiro-Wilk) and homogeneity of variances (Levene's test) of 
the data were assessed prior to statistical analysis. Permeation results were analysed 
statistically using one way analysis of variance (ANOVA) tests with post-hoc Tukey analysis 
where required. All other data were analysed using a Student's t-test. Statistically significant 
differences were assumed when p ≤ 0.05.  
 
The theoretical amount of solvents in the skin (sc and epidermis) was calculated on the basis 
of a literature reported steady-state flux of water at 0.2 mg.cm
-2
.h
-1 25-26
 and a measured 
steady-state flux of at PG at 9 mg.cm
-2
.h
-1
 (using PG at 240 µg.cm-2) and 1 mg.cm-2.h-1 (using 
PG at 2.2 µg.cm-2). These penetration rate values were expressed as a 3-D penetration rate 
(mg.cm
-3
.h
-1
) by taking into account the skin strata thicknesses. Using the solvent’s densities, 
the volume of PG and water penetrating the sc and epidermis was then calculated at 1 h post-
dose application, as described in equations 1 and 2.  
 
t
D
h
Flux
OvH
OH
sc
OH
sct ×












=
2
2
,2      (1) 
t
D
h
Flux
vPG
PG
sc
PG
sct ×










=,      (2) 
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Where vH2Ot,sc and vPG t,sc (mL) were the volumes of water and PG penetrating the sc at time 
t (1 h), FluxH2O and FluxPG were the steady-state flux values of water and PG (mg.cm
-2
.h
-1
), 
hsc the sc thickness (at 15 × 10
-4
 cm)  and DH20 and DPG were the density values for water and 
PG (mg.ml
-1
), respectively. The volumes of water and PG penetrating the epidermis at time t 
were determined in a similar manner by using the thickness of the epidermis, hep (at 100 × 10
-
4
 cm). The volume of endogenous water in each layer (vH2Oendog, sc estimated at 8.3 × 10
-4
 mL 
(sc water content = 20% w/w, wet density = 1.39 g.cm
-3
 
27
) and vH2Oendog, ep estimated at 5.1 
× 10
-3
 mL (epidermis water content = 60% w/w, wet density = 0.43 g.cm
-3
 (calculated from 
the reported dry density at 0.17 g.cm
-3 28
)) was added to the exogenous penetrating water in 
order to determine the v/v ratio of PG to water in the sc and the epidermis at 1 h (equations 3 
and 4): 
 
100%
,.2,2
.2,2
,2 ×







++
+
=
sctendogsct
endogsct
sct
vPGOvHOvH
OvHOvH
OvH   (3) 
100%
,.2,2
,
, ×







++
=
sctendogsct
sct
sct
vPGOvHOvH
vPG
vPG   (4) 
 
The current model assumed that there was no significant displacement of water molecules by 
PG and that the solvent’s penetration rate across the sc and the epidermis was homogeneous.   
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Results 
 
Formulation characterisation 
 
Analysis of the diclofenac formulation vehicle showed that the addition of water to PG at a 
volume ratio of 50:50 induced redshifts in the C-O stretching, CH stretching and OH 
deformation of PG (Fig SI 1a). These shifts confirmed the formation of PG-rich 
supramolecular complexes and a consequential reduction in water structuring in the co-
solvent system 
12
. This was further supported by the 4 cm
-1
 down-field shift in the bending 
vibration of pure water (D2O) when compared to the 50:50 PG:water solution (Fig SI 1b). 
The infrared spectra of the PG-water co-solvent was unchanged when the drug and polymer 
were added to the system and similarly the infrared spectra were unaffected by the in situ 
self-assembly process of the HPMC microparticles when the two spray solutions were mixed 
(i.e. mimicking the application of the InDicP formulation to the skin) (Fig.SI 1). 
 
Mixing PG and water without HPMC generated crystals with a different morphology 
compared to the diclofenac microparticles (Fig 1). The birefringence of both materials, when 
exposed to cross-polarised light, confirmed that they were crystalline in nature and this result 
suggested that the InDicP microparticles consisted of a diclofenac crystalline core in a HPMC 
shell. This finding accorded with the analysis of a similar system formed from a 70:30 PG-
water solvent mixture [20].  
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Figure 1. Diclofenac crystal morphology generated in the diclofenac supersaturated 
microparticle suspension (InDicP) (left) and that obtained in an equivalent control system 
without the polymer hydroxymethylcellulose (right).  The magnification used was × 200. 
 
Diclofenac permeated across silicone membrane rapidly with no transport lag-time when the 
InDicP was used to deliver the drug. Within the first 6 h, no donor phase dose depletion or 
receiver phase saturation occurred, and hence steady-state flux was measured in this time 
period (R
2
 > 0.99). Diclofenac steady-state flux, when applied as the InDicP formulation (at 
24.7 ± 6.4 µg.cm-2.h-1, n = 5 ± SD) was significantly higher (p < 0.05) than that obtained 
from a drug-saturated control (at 1.69 ± 0.13 µg.cm-2.h-1, n = 5 ± SD) (Supplementary 
information SI2). Using the calibration curve (Fig. 2 inset, data from Benaouda et al., 
22
), 
diclofenac DS in the solution state for InDicP during steady-state transport was calculated to 
be 15.6 ± 4.1.  
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Figure 2. Diclofenac degree of saturation in the diclofenac supersaturated microparticle 
suspension (InDicP) and the saturated control (Dic) (n =5 ± SD). The inset represents 
diclofenac transport calibration curve using a silicone membrane (n = 5 ± SD) (data from 
Benaouda et al., 
22
). 
 
Human skin studies 
 
PG permeated across the human ES to a similar extent (p > 0.05) when the InDicP and Dic 
formulations were used to apply a 240 µg.cm
-2
 dose of PG to the apical surface of the tissue 
(Figure 3). The steady-state flux of PG, at ca. 9 mg.cm
-2
.h
-1
, was recorded between 4-8 h, 
post-dose application. At 8 h post-dose application, the PG steady-state permeation was lost, 
since 23.3 ± 5.0 % and 37.5 ± 8.9 % of the applied PG using Dic and InDicP formulations, 
respectively, had permeated from the donor solutions. The PG flux reduced to ca. 1 µg.cm-
2
.h
-1 
after the 8 h time point and it remained at this rate for the subsequent 12 h.  
0
5
10
15
20
25
30
35
Dic InDicP
S
ili
c
o
n
e
 tr
a
n
s
p
o
rt
  r
a
te
 (
µ
g
.c
m
-2
.h
-1
)
DSInDicP = 15.6 ± 4.1
DSDic = 1
y = 1.59x - 0.08
R² = 0.99
0
4
8
12
16
20
0 2 4 6 8 10
T
ra
n
s
m
e
m
b
ra
n
e
 t
ra
n
s
p
o
rt
 r
a
te
 
(µ
g
.c
m
-1
.h
-1
) 
Degree of Saturation
Page 18 of 29
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. a) Diclofenac transport across human epidermal sheet when presented as drug-
saturated control (Dic, ◊), and as the diclofenac supersaturated microparticle suspension 
(InDicP, ♦). b) The cumulative mass of propylene glycol permeated using Dic (open bars) 
and InDicP (grey bars) formulations (n = 5-7 ± SD).  
 
The 1 h post dose time point was chosen to compare the co-solvent ratios in the skin as this 
was thought to provide the most accurate ‘snap shot’ of what was occurring in terms of 
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h post dosing time point the in silico calculations predicted that the application of the 240 
µg.cm
2 
of PG would produce 4.2 × 10
-3
 ml of PG per mg of sc and 2.0 × 10
-3
 ml of PG per 
mg of epidermis. The water content would be expected to be 9.5 × 10
-5
 ml per mg of sc and 
4.7 × 10
-5
 ml per mg of epidermis. From these values the PG-water (v/v) ratio was calculated 
to be 93:7 and 76:24 in the sc and epidermis, respectively (Fig. 4). Previous studies have 
shown that PG-rich supramolecular structures predominate at both these solvent ratios 
12
. 
 
 
 
 
 
 
 
Figure 4. Propylene glycol/water volume ratio changes upon solvent entry into the stratum 
corneum (SC) and epidermis at 1 h after the application of the diclofenac supersaturated 
microparticle suspensions using a high and a low PG loading dose. 
 
When the 240 µg.cm-2 dose of PG was used to apply the diclofenac to the apical surface of 
the skin its permeation across human ES was significantly faster (p < 0.05) compared to the 
drug-saturated control (the flux ca. 3.4-fold higher and the lag time ca. 3.5-fold lower) (Fig. 
3, Table 1). It was noted that 10 h after the application of the formulations the steady state 
permeation of the drugs seemed to cease and the drug flux slowed. At this time point both the 
drug-saturated control formulation, Dic, and the InDicP had delivered < 10% of the applied 
dose (at 7.1 ± 2.9 % (Dic) and 1.4 ± 0.1 % (InDicP)), hence drug depletion did not seem to 
drive the loss in steady-state observed in the transport profile (Fig. 3). As the loss of 
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diclofenac steady-state permeation occurred at the same time that PG depleted in the donor 
phase the change in flux was attributed to the associated change in PG transport into the skin.  
 
Table 1. Diclofenac and propylene glycol (PG) permeation parameters across human 
epidermal sheet (ES) following the application of diclofenac saturated control solution (Dic, 
n = 4 ± SD) or the diclofenac supersaturated suspension (InDicP, n  = 7 ± SD) using PG at a 
high loading dose. The parameters are: steady-state transmembrane rate (flux), lag time (TL), 
diclofenac mass retained in the epidermis at 26 h (Qepider., 26 h), the cumulative diclofenac mass 
permeated across the skin at 26 h (Qtransder., 26 h), the cumulative PG amount permeated at 8 h 
(Qtransder,8h), expressed as a fraction (%) of the applied PG, and the enhancement ratio (ER) 
compared to the control. 
 
 
Diclofenac Propylene glycol 
Flux 
(µg.cm-2.h-
1
) 
TL 
(min) 
Qepider., 26 h 
(µg.cm-2) 
Qtransder., 26 
h 
(µg.cm-2) 
Flux 
(mg.cm-2.h-1) 
Q transder, 8h 
(%) 
Dic 0.4 ± 0.2 115.2 ± 21.2 138.7 ± 11.7 20.5 ± 2.1 ** 23.3 ±  5.0 
InDicP 1.1 ± 0.2* 35.5 ±  10.7* 0.8 ± 0.1 5.6 ± 2.9 9.3 ± 4.4a 37.5 ± 8.9 
ER 3.4 ± 1.2 3.5 ± 1.2 174.3± 21.5 4.4 ± 1.6 - 1.7 ± 0.5 
*indicates statistical difference compared to the control (t-test, p < 0.01). 
** values below the assay’s LOD 
a  n = 3
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At 26 h post-dose application, for InDicP, the epidermal distribution of the diclofenac (at 
138.6 ± 11.7 µg.cm-2) was 174.3 ± 21.5 times higher (p < 0.05) than when the saturated 
control solution, Dic, was used to apply the drug to the apical surface of the skin (at 0.8 ± 0.1 
µg.cm-2) and this represented 22% (InDicP) and 2% (Dic) of the diclofenac available in the 
donor in the solution state. At this time point, the transdermal permeation of the drug was 4.3 
± 0.2 times higher (p < 0.05) for the InDicP compared to the Dic system (Table 1). The 
epidermal/transdermal distribution ratio of diclofenac was shown to be 6.8:1 and 0.1:1, 26 h 
after the dose application of InDicP and Dic, respectively. 
  
Reducing the PG loading dose to 2.2 µg.cm-2 produced an epidermal/transdermal distribution 
ratio of diclofenac of 0.7:1 for the InDicP system (Fig. 5) (epidermal diclofenac at 2.5 ± 0.9 
µg.cm-2 and transdermal diclofenac at 3.7± 1.9 µg.cm-2). On the basis of the PG steady-state 
measured in the previous permeation studies (at 9 mg.cm
-2
.h
-1
), it was anticipated that PG 
would rapidly deplete from the donor phase, and hence a PG flux of 1 µg.cm-2.h-1 was used to 
calculate the solvent skin distribution at 1 h after the formulation was applied to the skin. 
Using this PG flux value at the 1 h time point for the 2.2 µg.cm-2 PG loading the PG skin 
deposition was calculated to be  1.4 × 10
-4
 ml per mg of sc and 6.8 × 10
-5
 ml per mg of 
epidermis, whereas the water content was 2.8 × 10
-5
 ml per mg of sc and 1.4 × 10
-5
 ml per mg 
of epidermis. These values gave a PG-water (v/v) ratio of 38:62 in the sc and 10:90 in the 
epidermis 1 h after dose application (Fig. 4). Infrared spectroscopy analysis conducted 
previously in vitro suggested that at these v/v ratios water-rich solvent supramolecular 
structures prevail in the epidermal tissue 
12
.  
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Figure 5. Diclofenac epidermal and transdermal disposition at 24 h post-application of 
diclofenac supersaturated microparticle suspension using a high (grey bars) and a low (open 
bars) loading dose of propylene glycol (n = 5 ± SD).    
 
Discussion  
 
The PG:water matrix deposited on the surface of the skin by the two pump sprays supported a 
high diclofenac thermodynamic activity (DS ca. 16) despite the formation of the solid phase. 
These results were in accordance with previous work that generated a similar diclofenac 
microparticle suspension using a 70:30 (v/v) PG:water matrix 
20
. As described in previous 
work the microparticles were spherical in shape; they displayed a uniform size distribution 
and contained a crystalline core 
20
. Therefore, the microparticle suspensions were thought to 
act in a similar manner as the diclofenac suspensions employed for the permeation studies, 
whereby the solid phase acted as a reservoir that replenished the soluble diclofenac in order 
to sustain a high diclofenac thermodynamic activity 
20
. 
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The supersaturation of diclofenac in the formulation that occurred when the InDicP system 
was dosed to the apical surface of the skin provided the thermodynamic drive to allow the 
drug to move into the tissue rapidly. The FTIR analysis suggested that the 50:50 PG:water 
co-solvent ratio supported this process through the disruption of the water structuring in the 
vehicle, which increased the availability of hydrogen bond acceptors in the drug 
supersaturated solution. However, using a high PG loading dose generated an epidermal 
deposition of diclofenac that was 175-times higher than the saturated control and this 
exceeded the 16-fold increase that was expected from the drug supersaturated vehicle with a 
thermodynamic activity of 16 (a direct correlation between DS and flux with these systems 
has been shown in homogeneous membranes 
20, 22
). This suggested that the increase in the 
thermodynamic activity of the drug when it was applied to the skin was only in part 
responsible for the enhanced epidermal deposition showed by the spray formulation when 
compared to a drug-saturated control. 
 
The relationship between the loss of diclofenac and PG steady-state flux into the skin 
provided support to the notion that the solvent supramolecular structuring was influential in 
the transfer of the drug from the point of administration, on the apical surface of the skin, into 
the tissue. The significance of co-localising PG within skin tissue to the percutaneous 
penetration of several drugs has been previously discussed in the literature 
7, 9, 29
. For 
example, Trottet et al., reported that the depletion of PG from an applied formulation reduced 
the percutaneous transport of loperamide 
29
, while, Squillante et al., using 
14
C-PG, reported 
the concomitant percutaneous diffusion of PG and nifedipine 
9
. However, this previous work 
did not consider the significance of the rapid permeation of PG into the skin on the PG:water 
ratio within the tissue. The calculations performed in this work showed that the rate of PG 
entry into the skin produced a situation that allowed the excipient, at certain time points of 
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the permeation experiments, to dominate the interactions in the tissue. One consequence of 
the high PG levels in the skin tissue was that it would disrupt the normal drug-water and 
drug-tissue interactions due to its preferential association with the drug 
20
.  
 
The changes in the epidermal/transdermal distribution ratio of diclofenac after 24 h compared 
to the drug-saturated control suggested that the PG water co-solvent was promoting 
diclofenac penetration particularly into the epidermal tissue. PG has previously been found to 
localise in the skin at PG:water ratios similar to those calculated in this work; for example, 
the PG-water ratio was found to be 80:20 (v/v) in human sc following a 24 exposure to a 
60:40 PG-water mixture [10]). However, this previous work did not consider the potential to 
have different PG water ratios in the different skin strata and hence they did not determine the 
effect of this phenomenon on drug deposition in the skin. It was evident from the data 
gathered from present study that PG also had a particular skin deposition profile after topical 
application and that this profile could be altered through the application of different quantities 
of the excipient. High loading doses of PG applied to the skin produced high levels in the 
epidermis and this enabled diclofenac to preferentially reside in this skin strata. When the PG 
application dose was reduced by 100-fold, there was a marked change in the solvent skin 
distribution which was brought about by the rapid depletion of PG from the donor phase. A 
low level of PG in the skin reduced the PG in the sc and epidermis to such an extent that 
water became the predominant solvent in these layers of tissue (PG-water ratios at 40:60 (sc) 
and 10:90 (epidermis)). The consequence of water being the predominant solvent in the 
epidermis was that the preferential drug deposition was eliminated. 
 
Attempts to try and explain the diclofenac’s preferential residence in epidermis when 
accompanied by high levels of PG using Fedor’s solvency calculations did not improve the 
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understanding of the system 
30
. Calculating the solubility parameter of the skin (δ = 9.7-10 
(cal.cm
-3
)
1/2 31
), diclofenac (δ = 10.86 (cal.cm
-3
)
1/2
) and the potential changes in the solubility 
parameter of the skin upon the use of the high PG dose (δPG-water, epidermal = 16.5 (cal.cm
-3
)
1/2
) 
and low PG dose (δPG-water, epidermal = 22.5 (cal.cm
-3
)
1/2
) suggested that the PG rich solvent 
system should have very little benefit in localising diclofenac in the skin. However, Fedors 
method is based on the principles of ideal mixing, which does not apply to the PG-water 
solvent system. The inability of Fedor’s solvency calculations to explain the effects of the 
solvents indicates that the non-ideal mixing of the PG:water co-solvents was important in the 
manner in which the PG aided penetration of diclofenac into the skin. 
 
The direct FTIR analysis of the PG and water co-solvent interactions in the skin was not 
possible due to the overlapping of the spectra signals that provided the basis for the solvent-
solvent associations. Therefore, the interactions of the drug with the solvent at the ratios 
calculated to be in the skin at any given time point were based upon the previous FTIR 
analysis of binary PG-water mixtures at similar solvent volume ratios performed in vitro 
12
. It 
is accepted that the calculations of the solvent ratios in the skin may have contained 
inaccuracies due to the sourcing of reference values from different studies. However it was 
thought that these inaccuracies would not have a marked effect on the outcomes reported in 
this work, since the calculated values were unlikely to be altered by more than 10%. Such a 
value was predicted to be the critical value necessary to alter any solvent supramolecular 
structuring markedly. The in vitro FTIR data suggested that the predominance of PG-rich 
supramolecular complexes, accompanied with the loss of water structuring, would hold 
unionised diclofenac molecules in a drug solvent complex through physical interactions 
12
. In 
the current study, the PG-rich solvent complexes formed within the skin would be anticipated 
to display similar properties and hence this was used as the basis upon which to explain the 
Page 26 of 29
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27 
 
epidermal localisation of the diclofenac molecules when PG was the dominant solvent in the 
skin strata. When the PG loading in the application vehicle was reduced, water-rich solvent 
supramolecular structures were thought to be formed. These water rich structures have been 
shown to have a limited capacity to interact with the diclofenac molecules and hence such 
structures would be unlikely to retain diclofenac molecules within the skin to the same degree 
as when the tissue contains a high level of PG 
12
.  
 
Conclusion 
 
The epidermal localisation of diclofenac was thought to be facilitated in this study through 
the formation of PG rich supramolecular solvent structures within the skin. This effect was 
reversed when the PG levels dropped in the epidermis. FTIR data suggested that when only a 
small loading dose of PG was used to administer the diclofenac to the skin water rich 
supramolecular solvent structures dominated in the epidermis and such structures had a lower 
capacity to bind to diclofenac and retain the drug in the tissue. These findings require in vivo, 
confirmation but if similar effects are seen in man they would provide a sound basis for the 
design novel topical dosage forms that can control active agent delivery using supramolecular 
solvent complexes. These results clearly demonstrate that the formulation of topical vehicles 
is an integral facet of modulating the delivery of pharmaceutical compounds to the skin. 
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